Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Bortezomib/Liposomal doxorubicin (V-DD) is preferred to bortezomib single agent in salvage
therapy for Multiple Myeloma (MM).
The present study is designed to assessment the efficacy and safety study of Bortezomib in
combination with Liposomal Doxorubicin and Dexamethasone in treatment of Plasma Cell Leukemia
(PCL).
Primary study endpoint is the overall response rate (sCR+CR+VGPR+PR). Secondary endpoints is
the rate of complete response (sCR+CR), partial remission rate (VGPR + PR), duration of
response (DOR), overall survival (OS).
Phase:
Phase 2
Details
Lead Sponsor:
Clinical Service, China
Collaborators:
307 Hospital of PLA Beijing Chao Yang Hospital Chinese PLA General Hospital Harbin Hematology and Oncology Institute Harbin Institute of Hematology and Oncology Henan Provincial Hospital Henan Provincial People's Hospital Peking University Third Hospital Shanghai Changzheng Hospital Wuhan Union Hospital, China